Drug development can be complex and challenging. Researchers need to be decisive, strategic, and timely with planning and execution. Furthermore, they face the challenges of translating scientific knowledge of a respective disease’s predisposition and progression to create an effective therapy and finding the best approach to develop a new drug.
These challenges, coupled with the goals of drug development, are what unites all companies, regardless of their size or budget. Part one of our webinar series will examine the pros and cons of various approaches of development strategies used by companies of various structures and sizes.
Scientific Moderator and Presenters
Sam Chuang, PhD
Director, Scientific Advisory Services
VP Research and Development
Frank Brennan, PhD
Executive Director, Preclinical Safety
View the other webinars in the series:
- Developing Nonclinical Strategies for Human and Nonhuman Targets (View On Demand)
- The Future of Nonclinical Studies in the Age of COVID-19 (View On Demand)
During this time of uncertainty, we are focused on providing digital education options to keep you learning about topics you may be interested in. For more information, visit criver.com/digital-education.